Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more
Green Cross Lab Cell Corporation (144510) - Net Assets
Latest net assets as of September 2025: ₩431.56 Billion KRW
Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has net assets worth ₩431.56 Billion KRW as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩565.79 Billion) and total liabilities (₩134.23 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩431.56 Billion |
| % of Total Assets | 76.28% |
| Annual Growth Rate | 54.8% |
| 5-Year Change | 870.51% |
| 10-Year Change | N/A |
| Growth Volatility | 322.74 |
Green Cross Lab Cell Corporation - Net Assets Trend (2015–2024)
This chart illustrates how Green Cross Lab Cell Corporation's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Green Cross Lab Cell Corporation (2015–2024)
The table below shows the annual net assets of Green Cross Lab Cell Corporation from 2015 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩457.79 Billion | -15.46% |
| 2023-12-31 | ₩541.48 Billion | +0.56% |
| 2022-12-31 | ₩538.46 Billion | +5.37% |
| 2021-12-31 | ₩511.00 Billion | +983.32% |
| 2020-12-31 | ₩47.17 Billion | +7.08% |
| 2019-12-31 | ₩44.05 Billion | -7.69% |
| 2018-12-31 | ₩47.72 Billion | -1.25% |
| 2017-12-31 | ₩48.32 Billion | +0.47% |
| 2016-12-31 | ₩48.10 Billion | +436.82% |
| 2015-12-31 | ₩8.96 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Green Cross Lab Cell Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 651.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩31.26 Billion | 6.83% |
| Common Stock | ₩7.90 Billion | 1.73% |
| Other Components | ₩418.63 Billion | 91.45% |
| Total Equity | ₩457.79 Billion | 100.00% |
Green Cross Lab Cell Corporation Competitors by Market Cap
The table below lists competitors of Green Cross Lab Cell Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
C6K0
F:C6K0
|
$147.47 Million |
|
Limes Schlosskliniken AG
XETRA:LIK
|
$147.47 Million |
|
KENGIC Intelligent Technology Co. Ltd. A
SHG:688455
|
$147.48 Million |
|
Inogen Inc
NASDAQ:INGN
|
$147.49 Million |
|
FERRO SA ZY 1
F:0MN
|
$147.39 Million |
|
MN Holdings Berhad
KLSE:0245
|
$147.34 Million |
|
LITALICO Inc.
F:9N0
|
$147.31 Million |
|
Imperial Metals Corporation
PINK:IPMLF
|
$147.29 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Green Cross Lab Cell Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 534,021,181,480 to 457,789,877,600, a change of -76,231,303,880 (-14.3%).
- Net loss of 73,900,341,090 reduced equity.
- Dividend payments of 1,501,834,660 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩-73.90 Billion | -16.14% |
| Dividends Paid | ₩1.50 Billion | -0.33% |
| Other Changes | ₩-829.13 Million | -0.18% |
| Total Change | ₩- | -14.27% |
Book Value vs Market Value Analysis
This analysis compares Green Cross Lab Cell Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.86x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 5.73x to 0.86x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩4557.21 | ₩26100.00 | x |
| 2017-12-31 | ₩4578.66 | ₩26100.00 | x |
| 2018-12-31 | ₩4521.62 | ₩26100.00 | x |
| 2019-12-31 | ₩4173.68 | ₩26100.00 | x |
| 2020-12-31 | ₩4469.37 | ₩26100.00 | x |
| 2021-12-31 | ₩34028.67 | ₩26100.00 | x |
| 2022-12-31 | ₩35857.41 | ₩26100.00 | x |
| 2023-12-31 | ₩35547.75 | ₩26100.00 | x |
| 2024-12-31 | ₩30464.21 | ₩26100.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Green Cross Lab Cell Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -16.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -42.36%
- • Asset Turnover: 0.30x
- • Equity Multiplier: 1.26x
- Recent ROE (-16.14%) is below the historical average (3.25%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | 25.23% | 6.55% | 2.05x | 1.88x | ₩1.36 Billion |
| 2016 | 4.84% | 5.49% | 0.78x | 1.13x | ₩-2.48 Billion |
| 2017 | 2.19% | 2.31% | 0.83x | 1.15x | ₩-3.78 Billion |
| 2018 | 2.10% | 1.98% | 0.88x | 1.20x | ₩-3.77 Billion |
| 2019 | -5.17% | -3.93% | 0.85x | 1.55x | ₩-6.68 Billion |
| 2020 | 8.82% | 4.86% | 1.12x | 1.62x | ₩-556.92 Million |
| 2021 | 6.15% | 18.67% | 0.26x | 1.26x | ₩-19.68 Billion |
| 2022 | 4.53% | 10.32% | 0.35x | 1.26x | ₩-29.47 Billion |
| 2023 | -0.03% | -0.09% | 0.28x | 1.25x | ₩-53.58 Billion |
| 2024 | -16.14% | -42.36% | 0.30x | 1.26x | ₩-119.68 Billion |
Industry Comparison
This section compares Green Cross Lab Cell Corporation's net assets metrics with peer companies in the Diagnostics & Research industry.
Industry Context
- Industry: Diagnostics & Research
- Average net assets among peers: $36,677,693,049
- Average return on equity (ROE) among peers: -26.83%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Green Cross Lab Cell Corporation (144510) | ₩431.56 Billion | 25.23% | 0.31x | $147.39 Million |
| JOONGANG DNM Co.Ltd (051980) | $21.11 Billion | -86.57% | 0.65x | $76.18 Million |
| GeneMatrix Inc (109820) | $10.04 Billion | -20.13% | 1.07x | $21.74 Million |
| Genoray Co. Ltd (122310) | $87.96 Billion | 15.80% | 0.21x | $24.43 Million |
| Optipharm.CO.LTD (153710) | $35.44 Billion | -1.71% | 0.20x | $30.16 Million |
| Cytogen Inc (217330) | $48.58 Billion | -35.23% | 0.49x | $26.82 Million |
| U2Bio Co., Ltd. (221800) | $34.43 Billion | -8.25% | 0.31x | $84.67 Million |
| Gencurix Inc (229000) | $30.99 Billion | -111.87% | 0.78x | $21.52 Million |
| P&K Skin Research Center Co. Ltd (347740) | $74.24 Billion | 6.48% | 0.04x | $16.08 Million |
| Genesystem Co. Ltd. (363250) | $-12.70 Billion | 0.00% | 0.00x | $20.32 Million |